Fig. 3: B7-H3 CAR-T cells control metastatic CRC progression in vivo.

a, b Treatment schema and representative bioluminescence images of metastatic CRC tumors in mice bearing HT29 (a) and HCT116 (b) xenografts. c, d Bioluminescence kinetics of tumor progression in the metastatic CRC xenografts of HT29 (c) and HCT116 (d). e, f Survival curves of mice bearing HT29 (e) and HCT116 (f) xenografts. Data was analyzed by Kaplan-Meier survival analysis and log-rank test. **p < 0.01.